$1.66 2.2%
GANX Stock Price vs. AI Score
Data gathered: November 22

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Gain Therapeutics

Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is headquartered in Bethesda, Maryland.


Gain Therapeutics
Price $1.66
Target Price Sign up
Volume 194,630
Market Cap $44M
Year Range $0.94 - $4.37
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2401.8M-1.9M-4.5M00.000
Q2 '2441,0003.7M-3.7M-8.1M0-0.420
Q1 '24380,0001.9M-1.5M-4M0-0.220
Q4 '2302M-2M-4.7M0-0.360
Q3 '2302.5M-2.3M-4.7M0-0.370

Insider Transactions View All

Islam Khalid filed to buy 50,000 shares at $1.
August 12 '24
Mack Gene filed to buy 14,400 shares at $1.
August 12 '24
RICHMAN ERIC I filed to buy 277,629 shares at $1.2.
July 1 '24
RICHMAN ERIC I filed to buy 289,629 shares at $1.2.
July 1 '24
Riley Jeffrey Scott filed to buy 30,000 shares at $3.9.
April 1 '24

What is the Market Cap of Gain Therapeutics?

The Market Cap of Gain Therapeutics is $44M.

What is the current stock price of Gain Therapeutics?

Currently, the price of one share of Gain Therapeutics stock is $1.66.

How can I analyze the GANX stock price chart for investment decisions?

The GANX stock price chart above provides a comprehensive visual representation of Gain Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gain Therapeutics shares. Our platform offers an up-to-date GANX stock price chart, along with technical data analysis and alternative data insights.

Does GANX offer dividends to its shareholders?

As of our latest update, Gain Therapeutics (GANX) does not offer dividends to its shareholders. Investors interested in Gain Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Gain Therapeutics?

Some of the similar stocks of Gain Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.